'Secret' colony discovered hidden in impenetrable Aussie forest
It's only through the development of technology that University of Newcastle researchers were able to count the marsupials inside Sugarloaf State Conservation Area.
'Without drones there's no way we would have been able to get into Sugarloaf to survey. Trying to get ground search teams down into these areas would be virtually impossible,' PhD candidate Shelby Ryan told Yahoo News.
The University of Newcastle's Dr Ryan Witt said there had been an odd report of koalas in the area, but no confirmation of a stable population. Because the drone-mounted cameras can record imagery with strong detail, the researchers were able to verify joeys were present in the forest, meaning they are successfully breeding.
Related: Tiny speck in thermal photo confirms presence of increasingly rare animal
'The koala population at Sugarloaf seems to be a bit of a secret even though it's in close proximity to Newcastle,' he said.
Gamilaraay and Wiradjuri man Daryn McKenny grew up in the area but never saw koalas until recently. 'It wasn't until about five years ago that I first spotted a koala at Sugarloaf,' he said.
He's since been involved with helping the university team in their search for the marsupials. 'To know there's close to 300 is just incredible,' he said.
The Sugarloaf project was part of a survey of 67,300 hectares of bushland in NSW. It used a newly created counting model that combined thermal drone searches, spotlight verification and statistical modelling.
Funded by World Wide Fund for Nature-Australia and published in the journal Biological Conservation, the complete study estimated there were 4,357 koalas living across 208 sites. If money is secured for future surveys, then researchers will be able to track movements in population numbers.
In the immediate future, it's hoped the work will lead conservation efforts to help preserve the landscapes where the koalas live.
'We can protect and restore habitat, and try to reduce the impacts of road expansion and other infrastructure. It can also help us manage the threats of bushfires,' Ryan said.
In NSW and Queensland, experts predict koalas are on track to be extinct by 2050. In Victoria and South Australia, government surveys suggest koala numbers are stable and even overabundant in some areas. But there are concerns that development, habitat fragmentation, fire and the blue gum timber industry are creating a perfect storm that will soon see these populations also threatened.
Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
2 hours ago
- CBS News
Michigan DNR researchers set up trail cameras to monitor state's elk population
Researchers from the Michigan Department of Natural Resources have placed about 200 trail cameras throughout Northern Lower Michigan to help monitor the state's elk population. The trail camera network is part of a three-year research project that is aimed at determining an accurate and cost-effective way to manage the elk herd. The animal's territory includes about 1,100 square miles in that region. The DNR says Pigeon River Country State Forest is home to one of the largest wild elk herds in the eastern United States. Most of the cameras were placed on state-managed land, others are on private land where arrangements have been made with the property owners. DNR said the camera-based data will be compared with the more traditional aerial survey data to determine which method works the best. The next aerial survey is scheduled for 2026. That process takes about eight days, with two planes flying each day and two DNR researchers board each plane. The trail cameras are battery-operated, set about 40 inches off the ground, and use infrared and motion sensors to set off the cameras. The DNR will work with the Michigan Cooperative Fish and Wildlife Research Unit at Michigan State University to analyze the photos with AI technology and human review through their 2027 monitoring schedule. In another new research tactic, DNR staff will analyze teeth taken from elk that are harvested this fall and winter. Regardless of the method, population estimates are intended to help state officials make elk management decisions such as how many elk hunting licenses to issue each year.


Fox News
3 hours ago
- Fox News
Brain implant turns thoughts into digital commands
A new brain implant now lets people control Apple devices, such as iPads, iPhones, and the Vision Pro, using only their thoughts. Synchron, an endovascular brain-computer interface (BCI) company based in New York, demonstrated the first wireless BCI that works with Apple's official protocol. Ten patients have received the implant: six in the U.S. and four in Australia. With this technology, users living with severe paralysis can navigate apps, send messages, and operate devices hands-free. This breakthrough greatly expands independence, as it enables patients to manage their environment, stream shows, and control smart home devices, all using only their minds. Synchron's advancement in BCI technology marks a significant step for assistive devices and hints at how we may interact with computers in the future. The device's hands-free, voice-free operation offers a powerful new level of accessibility and autonomy for people with disabilities. Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts, and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide—free when you join my Synchron is the first company to connect a brain implant directly to Apple devices using Apple's official BCI Human Interface Device (HID) protocol. This means no custom hacks or workarounds. The system simply connects over Bluetooth, just like a keyboard or a mouse, and works with iPhones, iPads, and even the Apple Vision Pro. In a powerful video shared by Synchron, ALS patient Mark Jackson demonstrates the tech in action. After losing the use of his hands, he's now able to navigate his iPad entirely with thought. That includes opening apps, composing messages, and staying connected with the people he loves-all without moving a muscle. Behind the scenes, Synchron's system uses artificial intelligence to decode brain signals and turn them into real-time digital commands. Machine learning models interpret motor intent, such as thinking about tapping your finger, and translate that into actions on the iPad. This AI-powered decoding helps the system feel smooth and responsive as users learn to control it with focus alone. One surprising new feature is the built-in signal strength meter. This visual cue shows patients how strong their brain signal is in real time. A blue box appears over an icon or app and fills up based on how clearly the system reads the user's intent. It may sound simple, but this is a huge deal. It helps users like Mark fine-tune their mental focus, adjust their posture, and improve their interaction without outside help. It's like seeing your brain in action and learning to drive it better. "When I lost the use of my hands, I thought I had lost my independence," Mark says in the video. "Now, with my iPad, I can message my loved ones, read the news, and stay connected with the world, just by thinking." BCIs like Synchron's Stentrode and Elon Musk's Neuralink have connected to devices before, but never like this. Previous setups required custom software or physical adapters. Now, thanks to Apple's new BCI HID protocol, brain-computer interfaces can plug right into the Apple ecosystem like any other accessory. That official integration opens the door to more features, better performance, and fewer setup hurdles. Synchron's COO, Kurt Haggstrom, calls it a "game changer" for both patients and the entire BCI industry. This tech isn't just for people with paralysis, at least, not forever. Today, it's a medical tool undergoing trials. Tomorrow, it could become a consumer product you buy at your local Apple Store. With Apple embracing BCI as a legitimate input method, everything from your phone to your smart home could one day be controllable by thought. That opens the door for more accessibility, more customization, and completely new ways of interacting with technology. Think your devices and data are truly protected? Take this quick quiz to see where your digital habits stand. From passwords to Wi-Fi settings, you'll get a personalized breakdown of what you're doing right - and what needs improvement. Take my Quiz here: Synchron's Apple demo marks a new era in brain-computer interaction. It turns thoughts into action using mainstream tech you probably already own. While it's still in its early stages, the direction is clear: BCI is moving out of the lab and into real life, and Apple is helping lead the charge. Would you trust your brain to control your devices? Or is this one step too far? Let us know by writing to us at Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts, and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide—free when you join my Copyright 2025 All rights reserved.
Yahoo
4 hours ago
- Yahoo
SMSbiotech Initiates Groundbreaking Phase 1 Human Clinical Trial for COPD
MELBOURNE, Australia, August 21, 2025--(BUSINESS WIRE)--SMSbiotech, a San Diego–based leader in regenerative medicine, today announced the initiation of its first-in-human Phase 1 clinical trial for Chronic Obstructive Pulmonary Disease (COPD). This milestone marks the transition of years of dedicated research into clinical development, with the goal of delivering a transformative therapy for millions living with this debilitating lung condition. On July 11, 2025, at Veritus Research in Melbourne, Australia, the first dose of SMSbiotech's novel therapeutic candidate was administered to the inaugural patient. The Phase 1 study, titled "A study to investigate small mobile stem cells (SMS cells) in participants aged 39 to 69 years with chronic obstructive pulmonary disease," will enroll 18 COPD patients. The trial is designed to evaluate the safety and preliminary efficacy of SMSbiotech's Small Mobile Stem (SMS) cells—a unique, healthy, adult blood-derived cell population discovered and named by SMSbiotech. Unlike traditional treatments, SMS cells are designed to regenerate damaged lung tissue. The off-the-shelf, non-invasive therapy is administered directly to the lungs through a nebulizer. Preclinical studies demonstrated significant restoration of lung function in as little as 10 days. The study duration is expected to be 15 months. "The initiation of our Phase 1 trial for COPD is a profound moment for SMSbiotech and, more importantly, for the millions of patients yearning for better treatment options," said Dr. Abdulkader Rahmo, President of SMSbiotech. "We are also encouraged to report that the first two sentinel patients have been dosed, initial safety data has been received, and the trial can now move forward—an important validation step as we continue this study. We are immensely optimistic about the potential of our Small Mobile Stem cell therapy to not only manage COPD symptoms but to fundamentally alter the disease's progression and potentially reverse its devastating effects. We believe this represents a new dawn for respiratory medicine, offering the promise of a future where patients can breathe easier and live fuller lives." The trial received regulatory approval from the Therapeutic Goods Administration (TGA), Australia's regulatory authority equivalent to the U.S. Food and Drug Administration (FDA). SMSbiotech has filed 16 patents and received 7 granted patents for its technology. Pending sufficient safety data from this trial, the company plans to evaluate compassionate use applications. Encouraged by promising preclinical data, SMSbiotech is also investigating applications in orthopedics and other therapeutic areas. For more information about this clinical trial, please visit the Australian New Zealand Clinical Trials Registry at: Inquiries about study participation:Veritus ResearchPhone: +61 03 8736 1750Email: info@ About SMSbiotech SMSbiotech is a regenerative medicine company dedicated to advancing breakthrough therapies that restore tissue function and transform patient care. Leveraging its proprietary Small Mobile Stem (SMS) cell technology, SMSbiotech is focused on developing novel treatments for COPD and other debilitating diseases. View source version on Contacts Dr. Abdulkader Rahmoinfo@ 760-290-3406 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data